Clinical Trials Logo

Vascular Diseases clinical trials

View clinical trials related to Vascular Diseases.

Filter by:

NCT ID: NCT02878421 Completed - Vascular Diseases Clinical Trials

Vascular EffectS of regUlar Cigarettes Versus electronIc Cigarette USe

VESUVIUS
Start date: August 18, 2016
Phase: N/A
Study type: Interventional

The purpose of this study is to assess the effects of electronic cigarettes-nicotine and electronic cigarette-nicotine free on endothelial function as compared to traditional cigarettes. Due to ethical reasons, we cannot fully randomise all particpants to the three arms. Participants who wish to quit smoking will be randomized to 1. Switch to electronic cigarettes containing nicotine plus flavor 2. Switch to electronic cigarettes containing flavor alone Those who do not wish to quit smoking will continue on the Tobacco Cigarette arm Treatment period will be 28 days

NCT ID: NCT02869087 Completed - Clinical trials for Peripheral Vascular Disease

The DESappear Study: Drug Eluting Scaffold

DESappear
Start date: October 10, 2016
Phase: N/A
Study type: Interventional

The aim of this study is to prospectively collect information to evaluate the safety and performance of the Akesys Prava Sirolimus Eluting Bioresorbable Peripheral scaffold system for the treatment of symptomatic primary atherosclerotic stenoses and occlusions of the superficial femoral artery (SFA).

NCT ID: NCT02867501 Completed - Vascular Diseases Clinical Trials

Venous Distension in Patients With Aneurysmatic Arterial Disease

Start date: May 2016
Phase: N/A
Study type: Observational

The aim of the study is to assess if venous distension in patients with aneurysmatic arteriopathy is higher compared to patients with peripheral arterial occlusive disease (PAOD) and in controls.

NCT ID: NCT02863926 Completed - Clinical trials for Peripheral Artery Disease

Use of Autologous Concentrated Bone Marrow Aspirate in Preventing Wound Complications in Below Knee Amputation (BKA)

MarrowCHAMP
Start date: January 6, 2017
Phase: Phase 1
Study type: Interventional

Patients scheduled for major extremity lower amputation to receive bone marrow cells (cBMA) injected IM in the leg proximal to the amputation in the index limb to prevent ischemic wound complications after surgery.

NCT ID: NCT02861924 Completed - Vascular Diseases Clinical Trials

Locally Applied Pressure-induced Vasodilatation

LAV
Start date: October 11, 2016
Phase: N/A
Study type: Interventional

Measure microcirculatory responses after localized ischemia obtained by local application of pressure (laser speckle).

NCT ID: NCT02860858 Completed - Clinical trials for Symtomatic Macular Polypoidal Choroidal Vasculopathy

Intravitreal Aflibercept for Treatment of Polypoidal Choroidal Vasculopathy (PCV)

Start date: December 30, 2016
Phase: Phase 4
Study type: Interventional

Objective: To evaluate the efficacy of intravitreal aflibercept injection on visual acuity in patients with symptomatic macular PCV.

NCT ID: NCT02857894 Terminated - Clinical trials for Choroidal Neovascularization

Genetic Factors of Idiopathic Polypoidal Vasculopathies in the ATM Gene (Ataxia Telangiectasia Mutated)

ATM
Start date: November 5, 2015
Phase:
Study type: Observational

Polypoidal choriodal vasculopathy (PCV) is an ophthalmologic disease, characterized by vascular abnormalities of the walls of small choroidal vessels, reproducing the specific aspect of polyps (cluster aspect). PCV is one of the "boundary-forms" of age related macular degeneration. These vasculopathies can be idiopathic. Following the radiotherapy treatments of active and occult-typed neovessels in Age-Related Macular Degeneration (ARMD), 10% of the patients would present typical polypoidal vasculopathic lesions. These polypoidal secondary lesions have been induced by radiotherapy treatment and may show an increased sensibility to radiation in these patients. Such an increase of radiosensibility is noticed in ataxia telangiectasia syndrome, in relation to the ATM gene mutations. The secondary or idiopathic polypoidal vasculopathic lesions are to be brought closer to telangiectasias in Ataxia Telangiectasia. Considering the iatrogenic component of radiotherapy in the secondary forms of ataxia telangiectasia, it seems legitimate to search for predisposing variants to polypoidal vasculopathies in the ATM gene. Considering the frequency of PCV worldwide, it seems important to identify the predisposing genetic factors of the ATM gene. These biomarkers to the pathology might enable us to offer prevention (reinforced protection against radiations, including light) and to develop therapeutics (recruitment of other kinases, ATM's partners, in the stability and cellular control of DNA).

NCT ID: NCT02856230 Active, not recruiting - Clinical trials for Peripheral Vascular Diseases

An Efficacy and Safety Study to Evaluate Ranger DEB for BTK Angioplasty in Patients With CLI (RANGER-BTK)

RANGER-BTK
Start date: November 2016
Phase: Phase 2/Phase 3
Study type: Interventional

Endovascular treatment of below the knee disease is a well-established therapy to improve outcomes in patients with critical limb ischemia. Several large cohort studies demonstrated the safety and the efficacy of percutaneous recanalization and angioplasty for distal vessel disease. A successful recanalization of foot artery was related to a higher ulcer healing and a reduction of major amputation. Moreover absence of revascularization in a patient with critical limb ischemia is an independent risk factor for mortality. Despite the introduction of new devices dedicated to below the knee vessel disease treatment, with the development of guides and conical balloons, long term patency outcomes are still poor. Restenosis was observed in more than two thirds of patients within 3 months after angioplasty of tibial arteries with a high target lesions revascularization. These re-interventions are characterized by a higher morbidity and mortality due to several comorbidities associated to these patients. These data confirm the need to obtain more lasting results in order to improve long-term outcomes of these patients. Recently, the use of drug-eluting balloons (DEB) has revealed an increase in patency after angioplasty of the femoral artery. On the contrary, results for BTK arteries angioplasty have shown controversial results. The purpose of this study is to evaluate the safety and the efficacy of the Rangerâ„¢ SL paclitaxel coated balloon a model of drug eluting balloon in patients with critical limb ischemia.

NCT ID: NCT02854852 Completed - Vascular Diseases Clinical Trials

Photoplethysmography Detects Changes in Vascular Tone

Start date: March 15, 2017
Phase:
Study type: Observational

Changes in the vascular tone of anesthetized patients is common and cause hemodynamic problems. The monitoring of such changes in vascular resistance using simple and non-invasive tools is lacking. The present study was designed to determine if photoplethysmography can detect changes in the systemic vascular resistance using Doppler as the reference method.

NCT ID: NCT02850107 Completed - Clinical trials for Peripheral Vascular Disease

DiRectional AthErectomy + Drug CoAted BaLloon to Treat Long, CalcifIed FemoropopliTeal ArterY Lesions

REALITY
Start date: June 1, 2016
Phase: N/A
Study type: Interventional

This study is designed to collect information during a procedure that is routine care for treating a blockage in a blood vessel in the upper part of the participant's leg. This study is for data collection reasons to help doctors gain better understanding of the treatment of disease in the blood vessels of the legs. You will be treated with two devices that are routine, or standard of care, for your doctor to treat blockages in the blood vessel of the leg. The treatment is for a blockage or narrowing caused by plaque build-up in the blood vessel. Data will be collected to assess what length of time the blood vessel will be prevented from re-narrowing through twenty-four (24) months after the procedure.